Topical Skin-Target Blocking for Cancer Drug Toxicity Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for skin toxicities caused by systemically administered drugs, such as anti-neoplastic kinase inhibitors and biologics, fail to effectively prevent or diminish skin toxicities, leading to dose reduction or regimen interruption, and thus, existing methods do not effectively address dermatologic complications, impairing quality of life and necessitating dose modification and interruptions of anti-cancer treatments.
Innovation Solution
A novel methodology involving topical formulations of amine-containing, pyridine-based, pyrimidine-based, aniline-based, heteroaryl-containing, thieno pyridines, sulfonamides, and fluorinated aryl compounds to arrest, prevent, or reduce skin toxicities by blocking the binding of systemically administered drugs to their targets in the skin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical steroids, antibiotics, and skin moisturizers are used to treat skin toxicities, then some symptomatic relief may be achieved, but the treatments fail to effectively prevent or diminish skin toxicities, leading to dose reduction or regimen interruption
Solution Approach 1:
The patent applies preliminary anti-action by topically administering compounds that block the binding of systemically administered drugs to their targets in the skin before the toxic effects can manifest. This preventive approach stops the harmful interaction at the source, rather than merely treating symptoms after they occur, thereby maintaining treatment continuity without dose reduction
Solution Approach 2:
The patent uses topical compounds as intermediary substances that intervene between the systemically administered drug and its target in the skin. These intermediary compounds bind to the target sites first, preventing the systemic drug from interacting with skin cells, thus blocking the toxic pathway while allowing the systemic drug to continue its anti-cancer action
2Ease of operation
If current treatment regimens are used for skin toxicities, then some symptomatic management is provided, but the treatments do not show the efficacy needed, impairing quality of life
Solution Approach 1:
The patent introduces topical compounds as intermediary agents that specifically block drug-target binding in the skin. This targeted intervention provides effective prevention of skin toxicities while allowing continuous anti-cancer treatment, thereby improving both the efficacy of skin toxicity management and the overall quality of life during treatment
Solution Approach 2:
The patent applies local quality by using topical formulations that deliver protective compounds directly to the skin where the toxic interaction occurs. This localized application ensures high concentration of the protective agent at the target site without affecting systemic drug levels, providing effective skin protection while maintaining overall treatment efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively prevents or reduces skin toxicities, allowing patients to maintain optimal drug dosage and regimen, thereby improving quality of life and compliance with cancer treatments.
Implementation Method 1
topically administering at least one material prior to, concomitantly with or following administration of the at least one drug capable of inducing or causing skin toxicities, to thereby block the binding of the at least one drug to its target in the skin
Data Source
AI summary
Provided herein are methods for inhibiting binding of systemically administered drugs to a target in the skin by topically administering materials prior to or concomitantly with administration of the systemic drugs.